Genzyme leukemia drug wins FDA approval
640929
Shares of Cambridge-based Genzyme were up slightly today on news that the drug maker won approval for a drug to treat childhood leukemia.
501444
The Food and Drug Administration has approved a new drug for multiple sclerosis that in clinical trials got better results than existing drugs in protecting against relapses.
113986
The Food and Drug Administration strongly endorsed Biogen Idec Inc.&#39;s new multiple sclerosis treatment, putting the Cambridge firm in position to expand the market for MS drugs and win greater market share.
668214
WASHINGTON The Food and Drug Administration has approved a drug designed to better fight what&#39;s described as the leading cause of cancer-related deaths in America.
204544
Will Genzyme's Campath get approval?
297310
U.S. regulators have approved wider use of Genentech Inc. and Biogen Idec Inc.'s drug Rituxan for patients with a type of lymphoma, the companies announced on Friday.
641387
Federal health advisers recommended approval of the first new cancer drug in the past decade specifically aimed at treating the most common childhood leukemia.
432135
The Food and Drug Administration yesterday approved a cancer drug made by pharmaceutical giant Eli Lilly and Co. to treat advanced non-small cell lung cancer in patients who have undergone chemotherapy.
564004
Tysabri, a treatment for multiple sclerosis made by Biogen Idec Inc. and Elan Corp., received regulatory approval on Monday for use among patients with a severe intestinal disorder.
320147
Cancer drug shows exceptional promise as it moves toward FDA review.
494130
Genzyme Corp. announced Wednesday that its drug Clolar has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of children with difficult or relapsed acute lymphoblastic leukemia (ALL).
688289
The Food and Drug Administration approved Clolar, Genzyme Corp.'s new drug for patients under 21 with acute lymphocytic leukemia. An advisory panel on Dec. 1 recommended the drug be approved. Clolar was developed by Ilex Oncology Inc., the Texas firm Cambridge-based Genzyme acquired last week in a $1 billion stock transaction. The FDA panel recommended that more studies be done ...
577156
The Global Aids Alliance welcomes the approval of a generic Aids treatment by the US drug regulator.
295886
The U.S. Food and Drug  Administration said on Wednesday it had approved Amgen Inc's  drug Vectibix for the treatment of advanced colon cancer.
170831
GlaxoSmithKline Plc  has bought  global rights to Danish biotech company Genmab's  most  promising new drug, a treatment for leukemia, in a record deal  worth up to $2.1 billion, the two firms said on Tuesday.
108565
Danish biotech Genmab A/S on Tuesday signed a deal worth up to $2.1 billion with pharmaceutical company GlaxoSmithKline PLC for the global commercialization of a leukemia treatment.
96500
Genzyme Corp. , the biotech firm expanding into the market for cancer treatments, said fourth-quarter revenue rose 23 percent to $591 million on higher sales of its Cerezyme treatment for Gaucher disease. Revenue increased from $481 million a year earlier, the Cambridge company said in an e-mailed statement. Profit for the full year 2004, excluding some items, rose to $1.75 ...